Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
6.53
-0.35 (-5.09%)
At close: Mar 28, 2025, 4:00 PM
6.69
+0.16 (2.45%)
After-hours: Mar 28, 2025, 6:36 PM EDT
Atara Biotherapeutics Employees
Atara Biotherapeutics had 153 employees as of December 31, 2024. The number of employees decreased by 72 or -32.00% compared to the previous year.
Employees
153
Change (1Y)
-72
Growth (1Y)
-32.00%
Revenue / Employee
$842,745
Profits / Employee
-$558,190
Market Cap
38.26M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATRA News
- 23 days ago - Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - Business Wire
- 4 weeks ago - The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 6 weeks ago - The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 6 weeks ago - Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - PRNewsWire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 6 weeks ago - Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 7 weeks ago - Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - Accesswire
- 7 weeks ago - Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire